Dickran Kazandjian
University of Miami · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dickran Kazandjian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06910124 · Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After RelapseDickran Kazandjian, MD · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT06376526 · IMMUNOPLANT for Newly Diagnosed Multiple MyelomaDickran Kazandjian, MD · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05530421 · Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaUniversity of Miami · recruiting · Relapsed and Refractory Multiple Myeloma · principal investigator
- Ph2NCT01402284 · Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsNational Cancer Institute (NCI) · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:21 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.Oncologist · 2016373 citationsRCR 11.5
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.JAMA Oncol · 2015268 citationsRCR 8.1
- FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.Oncologist · 2014237 citationsRCR 6.3
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.Clin Cancer Res · 2016140 citationsRCR 3.9
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.Oncologist · 201666 citationsRCR 1.7
- 48 citationsRCR 1.3
- 44 citationsRCR 2.0
- 36 citationsRCR 1.1
- Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.Oncologist · 202118 citationsRCR 0.9
- Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.Sci Rep · 20197 citationsRCR 0.3